Search

Jeffrey Zwicker, MD, has been named Chief of the Hematology Service at Memorial Sloan Kettering Cancer Center (MSK). He joins MSK from Harvard University Medical School, where he was an Associate Professor of Medicine, and Beth Israel Deaconess Medical Center (BIDMC), where he served as Chief of Benign Hematology in the Division of Hematology since 2017. Dr. Zwicker succeeds MSK’s Interim Hematology Service Chief, Marcel van den Brink, MD, PhD.

… Wednesday, November 30, 2022 Jeffrey Zwicker, MD ,   has been named Chief of the Hematology Service at Memorial Sloan Kettering Cancer Center (MSK). He joins MSK from Harvard University Medical School, where he was an Associate Professor of Medicine, and   Beth Israel Deaconess Medical Center (BIDMC)

In honor of Women's History Month, meet the scientific hero who helped raise money and awareness for AIDS research.

… Wednesday, March 13, 2019 Summary In honor of Women’s History Month, we’re remembering female scientists from MSK’s past who shook up cancer research. Read about Charlotte Friend and Ora Rosen . In 1981, Mathilde Krim, an immunologist at the Sloan Kettering Institute , was exploring the role of naturally

A $10 million commitment from James H. and Marilyn H. Simons through the Simons Foundation will support preclinical initiatives undertaken as part of Memorial Sloan Kettering's new Brain Tumor Center (BTC).

… Thursday, January 31, 2008 A $10 million commitment from James H. and Marilyn H. Simons through the Simons Foundation will support preclinical initiatives undertaken as part of Memorial Sloan Kettering’s new Brain Tumor Center (BTC). Established in 2007, the BTC is designed to achieve fundamental new

After two studies examined the safety of eliminating axillary lymph node dissection (ALND) for some breast cancer patients, Memorial Sloan Kettering Cancer Center further tested their conclusions, confirmed the approach’s applicability and changed clinical practice.

… Thursday, June 23, 2016 Axillary lymph node dissection (ALND) is no longer the standard approach to the management of all breast cancer patients with metastases to the sentinel lymph nodes. Advances in mammography screening have resulted in lower nodal disease burden in women with axillary metastases

Michel Sadelain, MD, PhD, Director of the Center for Cell Engineering at MSK, has been awarded the Pasteur-Weizmann/Servier International Prize. Dr. Sadelain was chosen in recognition of his pivotal research demonstrating the therapeutic potential of engineered T cells.

… Tuesday, October 16, 2018 Michel Sadelain, MD, PhD, Director of the Center for Cell Engineering at MSK, has been awarded the Pasteur-Weizmann/Servier International Prize . Dr. Sadelain was chosen in recognition of his pivotal research demonstrating the therapeutic potential of engineered T cells. Dr.

The Ralph Lauren Corporate Foundation announced today that it's providing $25 million in new grant funding to expand or establish five Ralph Lauren cancer centers, aimed at reducing disparities in cancer care and access across underserved communities. The funding will benefit institutions including the Memorial Sloan Kettering (MSK) Ralph Lauren Center in Harlem.

… Wednesday, May 11, 2022 The Ralph Lauren Corporate Foundation announced today that it will provide $25 million in new grant funding to expand or establish five Ralph Lauren cancer centers, aimed at reducing disparities in cancer care and access across underserved communities in the United States. The

An annual report from an influential cancer group highlights three MSK studies that have advanced cancer research.

… Wednesday, January 28, 2015 Summary An annual report from an influential cancer group highlights three MSK studies that have advanced cancer research. Memorial Sloan Kettering is pleased to share the news that the American Society of Clinical Oncology (ASCO) has recognized three of our recent studies

Researchers gain insight into leptomeningeal metastasis, a devastating complication of advanced cancer.

… Friday, July 17, 2020 Summary Cancer that has spread to the fluid and tissues of the brain and spinal cord, called leptomeningeal metastasis , is difficult to treat. It was not clear how the cancer cells survive in this space. A new discovery shows the cancer cells reprogram themselves to outcompete

Memorial Sloan Kettering Cancer Center (MSK) and Curadev Pharma, Inc., a biotechnology company developing novel immuno-oncology therapeutics, are expanding their collaboration through the MSK Therapeutics Accelerator program to advance the development of CRD3874-SI, Curadev’s first-in-class allosteric stimulator of interferon genes (STING) agonist for solid tumors.

… Friday, June 20, 2025 Memorial Sloan Kettering Cancer Center (MSK) and Curadev Pharma, Inc., a biotechnology company developing novel immuno-oncology therapeutics, are expanding their collaboration through the MSK Therapeutics Accelerator program to advance the development of CRD3874-SI, Curadev’s first-in-class

Minimally invasive techniques, improved postoperative care, and a multidisciplinary approach help make Memorial Sloan Kettering Cancer Center’s rates of esophageal surgical morbidity and mortality among the country’s lowest.

… Friday, September 23, 2016 At Memorial Sloan Kettering Cancer Center (MSK), we have made significant strides in the management of esophageal cancer over the past ten years. Improvements in postoperative care and the introduction of minimally invasive techniques have decreased the number of postoperative